Table 1 Planned, ongoing or unpublished completed studies in the ICTRP as of 8 February 2023 evaluating small-molecule anti-infective drugs approved for human use but not included in current WHO recommended NTD strategies
WHO target NTD Source registry trial ID | Scientific title | Country of conduct | Registration datea Statusb |
|---|---|---|---|
Elimination | Â | Â | Â |
Onchocerciasis | Â | Â | Â |
 NCT02078024 ISRCTN50035143 | Comparison of ivermectin alone with albendazole (ALB) plus ivermectin (IVM) in their efficacy against onchocerciasis in the Volta Region, Ghana | Ghana | 20140228 (completed) |
 NCT04188301 PACTR 201906665550709 | Safety and efficacy of combination therapy with ivermectin, diethylcarbamazine, and albendazole (IDA) for individuals with onchocerciasis | Ghana | 20191202 20190624 Active, not recruiting |
 ISRCTN43697583 | The efficacy of rifapentine 900 mg/d plus moxifloxacin 400 mg/d given for 14 or 7 days against onchocerciasis: a randomized, parallel-group, open-label, phase II pilot trial | Ghana | 20150417 (completed) |
 PACTR202212910949177 | Exploiting the synergy of registered drugs rifampicin and albendazole to shorten the treatment duration of macrofilaricide for the cure of onchocerciasis in areas co-endemic with loiasis: an exploratory pilot phase II clinical trial study | Cameroon | 20221219 (not yet recruiting, last follow-up December 2025) |
 ISRCTN38954299 | Assessment of the efficacy of 7-14 days treatment with either high dose rifampicin 35 mg/kg/day plus albendazole (400 mg/day), rifampicin 10 mg/kg/day plus albendazole (400 mg/d) or doxycycline 200 mg/day plus albendazole (400 mg/day) in the treatment of onchocerciasis: a randomized, controlled, parallel-group, open-label, phase II pilot trial Cameroon | Cameroon | 20210604 Active, not recruiting, last follow-up May 2023) |
 PACTR 202009704006025 | The efficacy of rifampicin 35mg/kg/d plus albendazole 400mg/d given for 7 or 14 days against lymphatic filariasis and onchocerciasis: a randomized, controlled, parallel-group, open-label, phase II pilot trial | Ghana | 20200713 Recruiting (last follow-up Dec. 2024) |
Loiasis | Â | Â | Â |
 ISRCTN14889921 | Pre-treatment of loiasis caused by the parasitic African eye worm Loa loa in Gabon with the antiparasitic medication albendazole among patients with a high risk of adverse events after another antiparasitic administration, ivermectin | Gabon | 20221129 (retrospectively) Projected completion February 2023 |
 PACTR201807197019027 | Safety and efficacy of different albendazole-based treatment regimens to reduce microfilaraemia in subjects infected by Loa loa in an endemic area of Gabon: a randomised controlled open-label pilot study [3 weeks albendazole 400mg bid vs. 3 weeks albendazole followed by 2 weeks albendazole vs. 3 weeks albendazole followed by a single dose of 150 µg/kg ivermectin as soon as microfilarial loads have dropped to < 4000 mf/ml in > 90% of subjects vs. no treatment | Gabon | 20180607 (retrospectively) Completed |
Elimination as public health problem | Â | Â | Â |
Chagas disease | Â | Â | Â |
 Registro Brasileira de Ensaios Clinicos ID: RBR-5n4htp | Disulfiram repurposing in the combined chemotherapy of Chagas disease—phase I/II clinical trial | Brazil | 20200217 Recruiting |
Lymphatic filariasis | Â | Â | Â |
 PACTR202009704006025 | The efficacy of rifampicin 35mg/kg/d plus albendazole 400mg/d given for 7 or 14 days against lymphatic filariasis and onchocerciasis a randomized, controlled, parallel-group, open-label, phase II pilot trial | Ghana | 20200713 Recruiting (last follow-up Dec. 2024) |
 ISRCTN15320064 | Comparing the effectiveness of test and treat approaches with doxycycline or the triple-drug therapy with ivermectin/diethylcarbamazine/albendazole vs. ivermectin/albendazole for targeted elimination of lymphatic filariasis in a phase III clinical trial | Ghana | 20220,329 Not yet recruiting (last update August 2022) |
Schistosomiasis | Â | Â | Â |
 NCT03893097 | A proof-of-concept trial to evaluate artesunate-mefloquine as a novel alternative treatment for schistosomiasis in African children | Senegal | 20190328 Completed |
STH including strongyloidiasis | Â | Â | Â |
 PACTR202011642671155 | An adaptive phase II/III single-blinded, randomized, multi-centre, parallel-group, active-controlled, superiority study to evaluate the safety and efficacy of a single day or 3-day single dose of an albendazole-ivermectin coformulation vs. albendazole for the treatment of soil-transmitted helminth infections (Trichuris trichiura, hookworm, Strongyloides stercoralis) in paediatric and young adult population | Kenya, Mozambique, Ethiopia | 20201015 Recruiting Last follow-up 31 July 2023 |
Control | Â | Â | Â |
Dengue | Â | Â | Â |
 NCT03432442 | Pharmacokinetics and pharmacodynamics of ivermectin in pediatric dengue patients | Thailand | 20180214 Completed (last update February 2021) |
 CTRI/2021/09/036661 | Role of doxycycline in the treatment of dengue infection | India | 20210920 Not yet recruiting (last update September 2021) |
Buruli ulcer | Â | Â | Â |
 PACTR202209521256638 | Shortening Buruli ulcer treatment: WHO recommended vs. a novel beta-lactam-containing therapy—phase III evaluation in West Africa [rifampicin plus clarithromycin (RC) for 8 weeks vs. RC plus amoxicillin/clavulanate for 4 weeks] | Ghana, Côte d’Ivoire, Togo | 20220912 Planned start December 2022, planned final follow-up November 2023 Not yet recruiting |
 NCT05169554 | Beta-lactam containing regimen for the shortening of Buruli ulcer disease therapy: comparison of 8 weeks standard therapy (rifampicin plus clarithromycin) vs. 4 weeks standard plus amoxicillin/clavulanate therapy (RC8 vs. RCA4) | Benin | 20211227 Recruiting, Primary outcome data November 2024 |
Cutaneous leishmaniasis | Â | Â | Â |
 IRCT20140211016554N4 | Evaluation of the effectiveness of oral dapsone with intralesional antimoniate in treatment of cutaneous leishmaniasis in comparison with intralesional antimoniate alone | Islamic Republic of Iran | 20190428 Completed |